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Background: The search for better non-invasive biomarkers for gastric cancer remains ongoing. We investigated
the predictive power of serum trefoil factor (TFF) levels as biomarkers for gastric cancer in comparison with the
pepsinogen (PG) test.
Methods: Patients with gastric cancer, chronic atrophic gastritis (CAG) or chronic non-atrophic gastritis (CNAG), and
healthy people were recruited. Serum concentrations of TFFs, PG I, and PG II, as well as the presence of antibodies
against Helicobacter pylori, were measured by enzyme-linked immunosorbent assays (ELISA). Receiver operating
characteristics (ROC) were used to compare the predictive powers of the selected factors.
Results: The serum concentrations of TFF1, TFF2, and TFF3 in the control groups were significantly lower than
those in the gastric cancer group with the exception of TFF2 which was elevated in CAG. The area under the ROC
curve for TFF3 was greater than that for the PG I/II ratio (0.81 vs 0.78). TFF3 also had a significantly higher predictive
power for distinguishing gastric cancer than the PG test (odds ratio: 10.33 vs 2.57). Moreover, combining the serum
TFF3 and PG tests for gastric cancer had better predictive power than either alone.
Conclusions: Serum TFF3 may be a better predictor of gastric cancer than the PG test, while the combined testing
of serum PG and TFF3 could further improve the efficacy of gastric cancer screening.
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Gastric cancer is the second most frequent cause of cancer
death. Approximately one million new cases of gastric
cancer are diagnosed annually worldwide [1]. In most
countries, including China, gastric cancer is usually de-
tected at an advanced stage when the prognosis is poor.
In Japan, an extensive screening program using photo-
fluorography and endoscopy has succeeded in diagnos-
ing the majority of gastric cancers at earlier stages,
which has led to a 40–60% decrease in associated mor-
tality [2-4]. However, widespread endoscopy screening
is currently unavailable in China. Therefore, the pre-
selection of high-risk individuals with a simple and ef-
ficacious non-invasive biomarker, prior to endoscopic* Correspondence: huangzg@foxmail.com
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unless otherwise stated.examination, has been proposed as a reasonable stra-
tegy for gastric cancer mass screening.
Serum pepsinogen (PG) testing, a current method for
gastric cancer screening, has the advantage of being sim-
ple and inexpensive. It has been used as part of large-scale
screening in Japan. However, because of insufficient evi-
dence, the PG test has not yet been recommended for
population-based screening [5,6]. Moreover, while a com-
bination of serum PG and Helicobacter pylori (HP) anti-
body testing has been reported to be superior to PG
testing alone for predicting gastric cancer risk, this
method has also not yet reached a level where it can be
directly used to screen for gastric cancer [7].
The trefoil factor (TFF) family consists of three thermo-
stable and protease-resistant proteins, TFF1, TFF2, and
TFF3 [8]. These proteins are thought to play a pivotal role
in mucosal protection against damage [9]. Their onco-
genic potential has also been reported to be associatedLtd. This is an Open Access article distributed under the terms of the Creative
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and angiogenesis [10-16]. The expression of these peptides
in the gastrointestinal tract occurs in a tissue- and cell-
specific manner. TFF1 and TFF2 are predominantly
expressed in gastric mucosa [17], while TFF3 is expressed
in goblet cells of the intestine and also at lower levels in
other organs such as the breast, salivary gland, respiratory
tract, and hypothalamus [18-22]. Recently, serum levels of
TFFs in cancer patients, including those with gastric can-
cer, have been reported to be increased and therefore
could be useful biomarkers for screening [23-27].
In our study, we investigated the serum levels of TFFs
in patients with gastric cancer. The efficacy of serum
levels of TFFs as biomarkers of gastric cancer was fur-
ther analyzed in comparison to PG testing.
Methods
Subjects
Seventy-two patients with gastric cancer who underwent
treatment from January 2012 to October 2012 at the De-
partment of Gastrointestinal Surgery at the Ningbo
Medical Center of Lihuili Hospital were recruited for
this study. Serum samples were obtained before treat-
ment. Clinicopathological data including the TNM stage
of tumors and the histological type, according to Lauren
classification, were also collected. Sixty-one patients with
chronic atrophic gastritis (CAG) and 27 patients with
chronic non-atrophic gastritis (CNAG) were also re-
cruited from the Department of Gastrointestinal Endos-
copy from March 2012 to July 2012. CAG and CNAG
were diagnosed by endoscopic pathohistology, where
CAG was defined as a loss of gastric glandular cells or
their replacement by intestinal and fibrous tissue in the
antrum or corpus of the fundus by biopsy. The serum
samples of 37 healthy people, who reported no history of
upper gastrointestinal disorders, were obtained from the
Health Check Center of Lihuili Hospital from July 2012
to October 2012. Subjects were excluded if they presented
with severe comorbidities including hepatic, renal, cardio-
pulmonary, and hematologic disease, or had previously
undergone upper gastrointestinal surgery or vagotomy.
Written informed consent was obtained from all partici-
pants in accordance with the Declaration of Helsinki.
Approval from the research ethics committee of Lihuili
Hospital was also obtained.
Immunoassays for TFFs, Pepsinogen I, Pepsinogen II, and
Anti-HP IgG
Serum collected from fasted patients with gastric cancer,
CAG and CNAG, or the healthy controls were stored
at -80°C until analysis. Serum TFFs, pepsinogen I, pep-
sinogen II, and anti-HP immunoglobulin (Ig) G levels
were measured by enzyme-linked immunosorbent as-
says (ELISA).Specifically, serum levels of TFF1, TFF2, and TFF3 were
measured using commercial ELISA kits purchased from
USCN Life Science (Wuhan, China) and performed ac-
cording to the manufacturer’s instructions. Briefly, puri-
fied polyclonal antibodies were coated onto a 96-well
microtiter plates. Next, 100 μl of assay buffer, as a negative
control, serum samples, or dilutions of the appropriate
human TFF standard, were added to their respective wells
and the plates were incubated for 2 h at 37°C. The plates
were then washed and the appropriate diluted biotin-
labeled TFF polyclonal antibody was added to each well.
After incubation for 1 h at 37°C, the plates were washed
and diluted streptavidin conjugated to horseradish perox-
idase was added to each well. Following incubation for a
further 30 min at 37°C, the plates were washed and tetra-
methyl benzidine (TMB) solution was added for 20 min at
37°C. Finally, stop solution was added to each well, and
the absorbance at 450 nm was measured. The concentra-
tions of human TFFs in the samples were then calculated
from the working standard curve. The assay sensitivities
for TFF1, TFF2, and TFF3 were 44, 13.5 and 52 pg/ml,
respectively.
The serum concentrations of PG I and PG II were
measured by chemiluminescent enzyme immunoassay
kits from Biohit Plc (Helsinki, Finland). The serum PG
status was considered positive (PG +) for predicting gas-
tric cancer when the serum PG I level was ≤ 70 ng/mL
and the PG I/II ratio was ≤ 3.
HP infection was diagnosed by the detection of serum
HP IgG antibody using a commercial enzyme immuno-
assay kit (Biohit Plc).
Statistical analysis
All statistical analysis was performed using Graphpad
Prism 5.01 (La Jolla, CA, USA). Continuous data of pa-
tients and controls were firstly checked to confirm
whether they were close to a normal distribution, and
then statistically analyzed by t-test for normal distribu-
tions or by the Mann—Whitney test for non-normal dis-
tributions. A two-sided P value of <0.05 was considered
statistically significant. The receiver operating character-
istic (ROC) curves and the area under these curves
(AUC) were calculated to compare the predictive powers
of selected factors.
Results
Baseline characteristics of patients and controls
The baseline characteristics of the study subjects are
shown in Table 1. The average age of the 72 patients with
gastric cancer was 61.7 ± 1.4 years (male/female ratio =
1.23), and that of the 61 CAG—patients was 56.7 ±
1.4 years (male/female ratio = 0.91), thus there was a 5-
year age difference between the two groups. The average
age of CNAG patients was 48.1 ± 2.8 years, and that of
Table 1 The baseline characteristics and HP infection status, serum PG test of gastric cancer and controls
Gastric cancer (n = 72) CAG (n = 61) CNAG (n = 27) Healthy control (n = 37)
Age(years, mean ± SD) 61.7±1.4ζ 56.7±1.4 48.1±2.8 56.7±2.8





Early gastric cancer 16(22.2%)
Advanced gastric cancer 56(77.8%)
HP infection status
HP positive 48(66.7%) 30(49.2%) 14(51.8%) 18(48%)
PG test
PG I (ng/ml) 76.91±4.78* 72.02±5.48 79.64±5.74 84.52±4.44
PG II (ng/ml) 25.10±2.35** 19.44±1.27 18.27±1.93 14.39±1.12
PG I/II ratio 3.91±0.29ξ 3.99±0.24 5.84±0.72 7.18±0.69
ζ: No difference between gastric cancer and healthy group (P = 0.08); gastric cancer vs CAG P = 0.0179; gastric cancer vs CNAG, P < 0.001.
*: No difference between cancer group and CAG, CNAG and healthy group.
**: Gastric cancer vs. CAG, P = 0.0459; gastric cancer vs. CNAG, P = 0.0927; Gastric cancer vs. healthy, P = 0.002.
ξ: Gastric cancer vs. CAG, P = 0.8485; gastric cancer vs. CNAG, P = 0.0038; gastric cancer vs. healthy, P < 0.0001.
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group was 8.6 years younger than the healthy group.
In the gastric cancer group, 16 (22.2%) patients had
early stage gastric cancer (stage 0, IA and IB), while 56
(77.8%) patients had advanced gastric cancer. Accord-
ing to Lauren classification, 47 (65.3%) patients pre-
sented with diffuse type gastric cancer, while the other
25 (34.7%) showed intestinal type. The HP infection
status was very close with a HP + range of 48—66.7%
across groups. Serum levels of PG I were also not sig-
nificantly different between patients with gastric can-
cer and healthy controls. Serum levels of PG II,
however, were significantly higher in the gastric cancer
group than those in the healthy group. The PG I/II ra-
tio in the gastric cancer group was significantly lower
than that for controls with the exception of the CAG
cases (Table 1).
Serum concentrations of TFFs
The serum concentrations of TFF1, TFF2, and TFF3, in
patients with gastric cancer, CAG and CNAG, and in
the healthy groups, are shown in Figure 1. In patients
with gastric cancer, the mean serum TFF1 concentration
was 1.30 ± 0.15 ng/ml (95% CI [1.01, 1.59]), while in
CAG, CNAG, and the healthy group it was 1.07 ±
0.14 ng/ml (95% CI [0.77, 1.35]), 0.70 ± 0.08 ng/ml (95%
CI [0.53, 0.87]), and 0.72 ± 0.07 ng/ml (95% CI [0.58,
0.86]), respectively. Further statistical analysis revealed
that the mean serum TFF1 level in gastric cancer was sig-
nificantly higher than those in both CNAG (P = 0.0075)
and healthy group (P = 0.0045) patients, however, it wasnot significantly different from that in CAG (P = 0.1332).
The mean serum TFF2 concentration in patients with gas-
tric cancer was 1.08 ± 0.07 ng/ml (95% CI [0.93, 1.23]),
which was significantly higher than those in CAG (0.86 ±
0.07 ng/ml, 95% CI [0.71, 1.00], P = 0.034), CNAG (0.64 ±
0.08 ng/ml, 95% CI [0.47, 0.81], P = 0.0011), and healthy
(0.63 ± 0.05 ng/ml, 95% CI [0.53, 0.74], P < 0.0001) group.
The mean TFF3 serum level in gastric cancer patients was
also significantly higher than those in the other groups. In-
deed, the mean serum TFF3 concentration in patients
with gastric cancer was 50.95 ± 2.31 ng/ml (95% CI
[46.35, 55.55]), while in CAG, CNAG and healthy groups
it was 31.41 ± 1.34 ng/ml (95% CI [28.74, 34.09], P <
0.0001), 32.30 ± 2.09 ng/ml (95% CI [28.00, 36.59], P <
0.0001) and 30.67 ± 2.20 ng/ml (95% CI [26.22, 35.13],
P < 0.0001), respectively.
ROC analysis of serum TFF and the PG test as indicators
of gastric cancer
ROC analysis was performed to evaluate the accuracy of
serum concentrations of TFFs and the PG I/II ratio for
the diagnosis of gastric cancer. The area under the curve
for TFF1, TFF2, TFF3, and the PG I/II ratio were 0.67
(95% CI [0.56, 0.77]), 0.74 (95% CI [0.65, 0.83]), 0.81
(95% CI [0.72, 0.89]) and 0.78 (95% CI [0.69, 0.87]), re-
spectively (Figure 2A). Thus ROC curves indicated a
higher observed accuracy for TFF3 when compared with
that for the PG I/II ratio. In contrast, for CAG, the area
under the curve for TFFs showed significantly lower
values when compared with that for the PG I/II ratio
(Figure 2B).
Figure 2 ROC curves for concentration of serum TFFs and PG
I/II ratio to diagnose gastric cancer or CAG. (A) ROC curves for
concentration of serum TFFs to diagnose gastric cancer compared
with PG I/II ratio. The area under the curve of serum TFF1, TFF2,
TFF3 and PG I/II ratio was 0.67, 0.74, 0.81 and 0.78, respectively. The
results showed that serum TFF3 has a greater predictive power for
gastric cancer than PG I/II ratio. (B) ROC curves for concentration of
serum TFFs and PG I/II ratio to diagnosis CAG. The area under the
curve of TFF1, TFF2, TFF3 and PG I/II ratio was 0.63, 0.61, 0.53 and
0.76, respectively. The results presented that PG I/II ratio is an
obviously better marker for CAG detection than all of serum TFFs.
Figure 1 Concentration of serum TFFs measured by ELISA. Concentration of serum TFFs in patients with gastric cancer were significantly
higher than the other control groups.
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lated by ROC, were 1.0 ng/ml, 0.7 ng/ml, and 42.0 ng/
ml, respectively. The sensitivity and specificity of TFF1
were 58.33% and 72.97%, respectively, and the odds ratio
was 3.78. The sensitivity and specificity of TFF2 were
65.28% and 70.27%, respectively, and the odds ratio was
4.44. The sensitivity and specificity of TFF3 were 66.67%
and 83.78%, respectively, the odds ratio was 10.33. The
sensitivity and specificity of PG + were 37.5% and
81.08%, respectively, and the odds ratio was 2.57. These
data suggest that the serum concentrations of TFFs, es-
pecially TFF3, are significantly associated with gastric
cancer as demonstrated by the significantly higher odds
ratios than that determined for the PG test (Table 2).
Effect of HP infection on the ROCs of serum TFFs
To further evaluate the predictive power of TFFs and
PG I/II, the gastric cancer and healthy groups were fur-
ther subdivided according to HP positivity and then
ROC analysis was performed. The AUC for HP positive
gastric cancer patients were significantly larger for TFF3
(0.83, 95% CI [0.73, 0.94]) and PG I/II ratio (0.86, 95%
CI [0.74, 0.98]) than those for either TFF1 or TFF2
(Figure 3A). In contrast, the AUC for HP negative group
was slightly smaller than that of HP positive. The AUC for
TFF3, TFF2, and PG I/II ratio were very close at 0.77, 0.75
and 0.72, respectively (Figure 3B). These results indicate
that TFF3 is a slightly better marker than PG I/II ratio for
detecting gastric cancer irrespective of the HP infection
status.
Effect of combining measurement of serum TFF3 and the
PG test for gastric cancer determination
We next analyzed the accuracy of using both the con-
centration of TFF3 and the PG test for detection of gas-
tric cancer. According to the criteria of PG +, 24 of the
72 gastric patients were detected by the PG test. How-
ever, when the serum TFF3 test was added, 54 of the 72gastric cancer patients with gastric cancer were detected,
that is, an additional 30 patients with gastric cancer who
were not identified by the PG test alone were picked up
by the serum TFF3 test. On the contrary, 6 patients with
gastric cancer who were not detected by serum TFF3
Table 2 Comparison of sensitivity and specificity of
serum TFFs and PG test for gastric cancer
Criteria Sensitivity Specificity Odds ratio
PG test (+) 37.50% 81.08% 2.57
TFF3 (≥42ng/ml) 66.67% 83.78% 10.33
TFF2 (≥0.7 ng/ml) 65.28% 70.27% 4.44
TFF1 (≥1.0 ng/ml) 58.33% 72.97% 3.78
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ity of the combined tests increased to 75%, the specifi-
city was decreased.
The relationships between serum TFFs and the
histological types and TNM stages of gastric cancer
The concentrations of serum TFFs were compared with
histological types and TNM stages of gastric cancer to
examine their influence on gastric cancer development
and progression. The concentration of serum TFF1 did
not significantly differ among different histological types
or TNM stages. The concentration of serum TFF2, was
significantly lower in patients with intestinal type than
diffuse type gastric cancer (0.87 ± 0.07 vs 1.19 ± 0.10, P =
0.0373), but it was not different between early and ad-
vanced stages of gastric cancer. The concentration ofFigure 3 For HP+/− patients, ROC curves of serum TFFs and PG
I/II ratio. (A) For HP positive patients, the area under the curve for
serum TFF1, TFF2, TFF3 and PG I/II ratio was 0.67, 0.72, 0.83 and 0.86,
respectively. Serum TFF3 and PG I/II ratio showed a good ROC curve.
(B) For HP negative patients, the area under the curve for serum
TFF1, TFF2, TFF3 and PG I/II ratio was 0.64, 0.75, 0.77 and
0.72, respectively.serum TFF3 in patients with intestinal type gastric can-
cer was significantly lower than that in diffuse type
(43.87 ± 2.74 vs 54.72 ± 3.10, P = 0.0242), it was also re-
duced in patients with early gastric cancer than in those
advanced gastric cancer (42.50 ± 3.32 vs 53.36 ± 2.74,
P = 0.0497) (Figure 4). As a control, PG I/II ratios were
not significantly different in either different histological
types or TNM stages of gastric cancer.
Discussion
Gastric cancer is one of the most common malignancies.
It is usually detected at an advanced stage where prog-
nosis is poor and the survival rate is low. To reduce
disease-related mortality and improve survival, better
biomarkers are needed for the screening and early detec-
tion of gastric cancer. The pepsinogen test has been
used for gastric cancer screening in Japan [28,29] and
has recently started to be used in China. The sensitivity
of the pepsinogen test has been reported to range from
45—77% with specificity ranging from 68—87% [30-32].
In the present study, the sensitivity of the pepsinogen
test was 37.5%, while its specificity was 81.1%, and the
odds ratio was 2.57. The relatively lower sensitivity of
the pepsinogen test in our study, when compared with
the reported range, may be associated with the use of
different PG immunoassay kits. Iijima K et al. [33] have
previously reported that serum PG I levels determined
using the GastroPenal test (Biohit Plc) were twice asFigure 4 Distribution of serum TFF3 in differentiated or
undifferentiated, early or advanced gastric cancer. The
concentration of serum TFF3 in patients with differentiated gastric
cancer was significantly lower than in undifferentiated group
(P = 0.0273). Serum TFF3 level in patients with early gastric cancer was
also significantly lower than in advanced gastric cancer (P = 0.0497).
The results showed that the concentration of serum TFF3 has
correlated with histological type and TNM stages of gastric cancer.
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PG assays with both kits were able to identify highly sig-
nificant correlations between PG concentration and gas-
tric cancer. Additionally, our results may be impacted by
the higher rate of diffuse type gastric cancers in our
study recruits. Indeed, serum PG II levels have been re-
ported to be increased in patients with diffuse type can-
cer [34]. In short, it seems that the PG test for gastric
cancer is easily influenced by various factors and there-
fore does not meet the ideal criteria for screening.
Kaise M et al. [35] were the first to report that serum
levels of TFFs, especially TFF3, are significantly linked to
the presence of gastric cancer. In our cohort, serum con-
centrations of TFFs showed significantly higher odds ra-
tios than the pepsinogen test. Of the three TFFs, the best
biomarker was serum TFF3 which had a sensitivity of
66.67%, a specificity of 83.78%, and an odds ratio of 10.33.
The comparative analysis of the pepsinogen test and
serum TFF concentrations for the screening of gastric
cancer further shed light on their respective predictive
power. We found that 48 (66.7%) of the 72 patients with
gastric cancer were negative for the pepsinogen test,
while the serum TFF3 test identified an additional 30,
the sensitivity of combining the results of serum TFF3
and pepsinogen tests was 75%, which was better than
that of either tests alone.
In the HP positive subjects, the AUC of serum TFF3
was very close to that of the PG I/II ratio (0.83 vs. 0.86).
In the HP negative subjects, however, the AUC of serum
TFF3 was slightly larger than that for the PG I/II ratio
(0.77 vs. 0.72). The serum TFFs and PG tests are both
based on histological changes in the gastric mucosa from
atrophic gastritis. In this study, HP infection was deter-
mined by measuring serum anti-HP IgG levels. However,
anti-HP IgG levels are reported to decrease when atro-
phic gastritis has extended to most of the fundic area of
the stomach after long-term HP infection [36]. Thus, HP
positive subjects in this study may include patients with
gastric cancer and non-cancer individuals with the same
extent of severity of atrophic gastritis. Subsequently, it is
difficult to screen for gastric cancer by using atrophic
gastritis related markers in this context. Indeed,the pre-
dictive power of the HP infection status was less than
that of either serum TFF3 or the PG test.
We also evaluated the relationship between TFF3 and
the histological type and stage in gastric cancer. We found
that serum concentrations of TFF2 and TFF3 in patients
with intestinal type gastric cancer were lower than those
in patients with diffuse type. Neither serum TFF1 or the
PG I/II ratio were significantly associated with either the
histological type or TNM stage. Muller et al. [37] has pre-
viously reported a highly significant correlation between
TFF1 expression and that of pepsinogen II, a marker of
gastric differentiation, in gastric adenocarcinoma tissue.However, there was no significant relationship between
TFF1 expression and the histological type of gastric can-
cer. Similarly, TFF1 knockout mice have been shown to
develop both gastric adenomas and carcinomas [38]. Fur-
thermore, TFF1 has been shown to be markedly down-
regulated in human gastric cancer [39]. These observa-
tions may explain to a certain extent why serum TFF1 and
the PG I/II ratio were not related with histological types
and TNM stages in gastric cancer. With respect to TFF2,
spasmolytic polypeptide (TFF2)-expressing metaplasia
(SPEM) has been frequently observed in the gastric mu-
cosa surrounding gastric cancer and TFF2 is reported to
be down-regulated (83.3%) in primary gastric cancer [40].
Thus the lower level of serum TFF2 in patients with intes-
tinal type gastric cancer may reflect the replacement of
SPEM with intestinal metaplasia. In contrast, TFF3 has
been reported to be up-regulated in most malignant tu-
mors including primary gastric cancer [23-27]. Moreover,
its expression has been correlated with a highly aggressive
phenotype and poor prognosis [41]. Im et al. further found
that TFF3 expression is higher in patients with undifferen-
tiated type gastric cancer, and that it significantly corre-
lated with advanced stages [39]. Thus, the results of our
study are highly consistent with these reports. However,
according to the histopathogenesis of gastric cancer, be-
cause TFF3 is strongly expressed by goblet cells in the
normal intestine and in the intestinal metaplastic epithe-
lium of the stomach, high expression of TFF3 would be
expected in differential type and intestinal type gastric
cancer. Further investigation is therefore needed to ex-
plain these mutually contradictory phenomena. Notably,
other studies have recently reported that serum TFF3 is
increased in patients with lung cancer, endometrial cancer,
and prostate cancer, and that TFF3 is expressed in the tis-
sue of these cancers [24,26,27]. Thus, elevated serum TFF3
levels may not be specific for gastric cancer. Therefore, the
origin of high serum TFFs also needs further examination.
One limitation of this study is the biased sampling
owing to its enrolment of subjects from a clinical series of
hospital cases mixed with healthy people from the health
check center of a hospital rather than a population-based
cohort. The number of study cases was also limited. Con-
sequently, further population-based studies or large clin-
ical cohort studies are required to confirm the strong
predictive power of serum TFF3 as well as that of its com-
bination with the PG test, and to thereby identify the pos-
sibility of serum TFF3 as a non-endoscopic biomarker in
population-based screening for gastric cancer.
Conclusions
To evaluate their use as potential biomarkers for
population-based screening, we explored the predictive
power of serum TFFs compared with that of the PG
test for the detection of gastric cancer. We found the
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ter biomarker of gastric cancer than the PG test. Sec-
ond, combination testing of serum PG and TFF3 could
improve the efficacy of gastric cancer screening. Third,
the serum TFF3 level has an association with the dif-
ferentiation type and TNM stage in gastric cancer. Our
findings therefore support serum TFF3 concentration
as biomarker for gastric cancer screening.
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